A Phase 2/3 interventional study of Dietary supplements - Nicotinamide and Pyruvate and Placebo in Primary Open Angle Glaucoma, sponsored by Columbia University. Active, not recruiting at 3 sites in United States. Open to participants aged 35 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Columbia University · Phase 2/3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.
Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 53rd largest by planned enrollment of the 279 interventional ones that give a count, is one of 14 that started in 2023, is one of 5 in phase 2/3, reaches primary completion later than 40 of the 66 other live ones, and was the 283rd registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:
Tavo Biotherapeutics · Sites in United States
Ages 18+
Brett King · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 20–79 · Healthy volunteers
YS Life Science Co., Ltd. · Sites in United States, India
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 35 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
348 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 99 · Phase 3 58 · Phase 4 36
First in 1976; this study’s year is marked. 14 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 84 across the 279 interventional studies, 100 across the 57 observational. Of the 260 that completed or were terminated, 117 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
228 of 348 have an industry lead sponsor. The 10 most frequent:
Columbia University is the lead sponsor of 1,136 studies on the registry; 194 are open to participants now.
Of its 182 completed or terminated interventional studies of FDA-regulated products, 150 (82%) have results posted.
Columbia University has 2 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
24 of the studies in Glaucoma, Open-Angle with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05695027Phase 3Columbia UniversityNicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study | 2027-08 |
| NCT07661329Phase 3YS Life Science Co., Ltd.A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension | 2027-11-01 |
| NCT05626426Stanford UniversityElectrical Stimulation for the Treatment of Optic Neuropathies | 2026-12 |
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT05506423Iantrek, Inc.Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes | 2026-12 |
Add all 24 to your calendar (.ics) → With an account.
Among the 348 studies in Glaucoma, Open-Angle with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N\&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma.
A total of up to 188 participants will be enrolled and randomized 1:1 to receive N\&P or placebo for 87 weeks (20 months). Participants will be followed for a total of 91 weeks (21 months).
Glaucoma is the leading cause of irreversible blindness worldwide. The most important test to detect progression is visual field testing or standard automated perimetry (SAP). The natural course of glaucoma includes a decline in visual function that matches optic nerve structural changes over time.
Both in clinical practice and in clinical trials, individuals undergo visual field testing at regular intervals in order to define whether progressive changes have occurred as well as the rapidity of change. Visual field results are highly variable within and between sessions, partly due to its subjective nature, which ultimately depends upon the test reliability, individuals' level of experience with the test, variability due to disease severity, and, importantly, the level of individual attentiveness during the test. Therefore, numerous attempts have been made to try to optimize individuals' performance during the test. Some of the approaches reported to date are listening to classical music mitigating background noise and use of nutritional supplements.
Recent studies have suggested that over-the-counter medications such as nicotinamide (vitamin B3) and pyruvate can also improve the performance during this test. The investigators are doing this research study to find out if taking nutritional supplements (vitamin B3 and pyruvate) available over- the-counter can help slow the rate of glaucomatous visual field progression compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The N\&P group will receive nicotinamide and pyruvate for 87 weeks (20 months).
Drug: Dietary supplements - Nicotinamide and Pyruvate
The placebo group will receive placebo for 87 weeks (20 months).
Drug: Placebo
Nutritional supplements
Placebo
Change in visual field results based on pointwise and global metrics
The primary outcome in this study are changes in visual field results based on pointwise and global metrics between intervention and placebo groups.
Time frame: 87 weeks
Change in retinal nerve fiber and ganglion cell layer thickness
The primary outcome in this study are changes in retinal nerve fiber and ganglion cell layer thickness as assessed by optical coherence tomography testing between intervention and placebo groups.
Time frame: 87 weeks
Plan to share: No
Started Mar 2023 (actual). Primary completion is estimated for Aug 2027, 53 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.